INDUSTRY VOICE: Big players in the healthcare sector are desperate to differentiate their approved 'checkpoint inhibitors' (a drug that unleashes an immune system attack on cancer cells) by combining their use with conventional chemotherapy or other new...
Previously owned by European private equity investor
Investing in new systems crucial
Focus on renewable energy
Tackling gender equality, hunger and education issues
Legacy technology remains primary obstacle
INDUSTRY VOICE: Despite market volatility in Q1, BB Biotech performed very well with an overall return of 8.8% in CHF. Several large biotech companies are currently trading below their fundamental value,and offer an attractive entry level for investors....
Major industry trend
Increased use of the 'digital ledger'
Ali Unwin explains the ongoing data-mining fallout that has engulfed Facebook in recent weeks, highlighting the implications for tech companies and the two biggest risks for the social media giant.
Report on managers' attitudes towards AI
Due to launch in Q2
With a total return of 23.1% in CHF and 13.1% in EUR buoyed by the euro's substantial appreciation against the dollar, BB Biotech delivered a strong performance in 2017 and will propose a record regular dividend of CHF 3.30 per share .
Net inflows of $604m in 2017
Under NatWest brand
Incorporating AI in Sustainable Equity fund approach
50-80 stock portfolio
Rising regulatory cost environment
Launched in 2003
Investment Week is delighted to honour the winners of our Fund Services Awards in categories including Best Compliance & Regulatory Solution and Best Fund Administration Team.
Research conducted by Roubini Thought Lab
iPhone X slated for launch on November 3